Cargando…

Interleukin-24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell

BACKGROUND: Acute promyelocytic leukaemia (APL) is a clonal disease arising by hematopoietic stem cell (HSC), which characterized by inappropriate proliferation/differentiation or survival of immature myeloid progenitors. Oncolytic adenoviruses have been under widespread investigation as anticancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Li, Ma, Jiabin, Qin, Lanyi, Shi, Xiaogang, Si, Hongqiang, Wei, Yahui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708966/
https://www.ncbi.nlm.nih.gov/pubmed/31145345
http://dx.doi.org/10.1097/MD.0000000000015875
_version_ 1783446099093094400
author Liu, Li
Ma, Jiabin
Qin, Lanyi
Shi, Xiaogang
Si, Hongqiang
Wei, Yahui
author_facet Liu, Li
Ma, Jiabin
Qin, Lanyi
Shi, Xiaogang
Si, Hongqiang
Wei, Yahui
author_sort Liu, Li
collection PubMed
description BACKGROUND: Acute promyelocytic leukaemia (APL) is a clonal disease arising by hematopoietic stem cell (HSC), which characterized by inappropriate proliferation/differentiation or survival of immature myeloid progenitors. Oncolytic adenoviruses have been under widespread investigation as anticancer agents. Recently, our data suggested that tumor cells were cured by AdCN205-IL-24, an adenovirus serotype 5-based conditionally replicating adenovirus expressing IL-24 after infection. METHODS: In this study, we created a novel fiber chimeric oncolytic adenovirus AdCN306-IL-24 that has Ad11 tropism and approved CAR (coxsackie adenovirus receptor, CAR)-independent cell entry, which could allow development of selective cytopathic effects (CPE) in APL cells in vitro. RESULTS: Formidable cytotoxic effect was specifically implemented in APL cells after infection with AdCN306-IL-24. The expression of IL-24 was up-regulated upon treated with accepted tumors. And the vector also induced superior cytolytic effects activity in APL cells by activation of programmed cell death. CONCLUSIONS: Taken together, our data suggested that chimeric oncolytic adenovirus AdCN306-IL-24 could express IL-24 gene, representing a potential therapeutics for acute promyelocytic leukemia.
format Online
Article
Text
id pubmed-6708966
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-67089662019-10-01 Interleukin-24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell Liu, Li Ma, Jiabin Qin, Lanyi Shi, Xiaogang Si, Hongqiang Wei, Yahui Medicine (Baltimore) Research Article BACKGROUND: Acute promyelocytic leukaemia (APL) is a clonal disease arising by hematopoietic stem cell (HSC), which characterized by inappropriate proliferation/differentiation or survival of immature myeloid progenitors. Oncolytic adenoviruses have been under widespread investigation as anticancer agents. Recently, our data suggested that tumor cells were cured by AdCN205-IL-24, an adenovirus serotype 5-based conditionally replicating adenovirus expressing IL-24 after infection. METHODS: In this study, we created a novel fiber chimeric oncolytic adenovirus AdCN306-IL-24 that has Ad11 tropism and approved CAR (coxsackie adenovirus receptor, CAR)-independent cell entry, which could allow development of selective cytopathic effects (CPE) in APL cells in vitro. RESULTS: Formidable cytotoxic effect was specifically implemented in APL cells after infection with AdCN306-IL-24. The expression of IL-24 was up-regulated upon treated with accepted tumors. And the vector also induced superior cytolytic effects activity in APL cells by activation of programmed cell death. CONCLUSIONS: Taken together, our data suggested that chimeric oncolytic adenovirus AdCN306-IL-24 could express IL-24 gene, representing a potential therapeutics for acute promyelocytic leukemia. Wolters Kluwer Health 2019-05-31 /pmc/articles/PMC6708966/ /pubmed/31145345 http://dx.doi.org/10.1097/MD.0000000000015875 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle Research Article
Liu, Li
Ma, Jiabin
Qin, Lanyi
Shi, Xiaogang
Si, Hongqiang
Wei, Yahui
Interleukin-24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell
title Interleukin-24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell
title_full Interleukin-24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell
title_fullStr Interleukin-24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell
title_full_unstemmed Interleukin-24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell
title_short Interleukin-24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell
title_sort interleukin-24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708966/
https://www.ncbi.nlm.nih.gov/pubmed/31145345
http://dx.doi.org/10.1097/MD.0000000000015875
work_keys_str_mv AT liuli interleukin24enhancingantitumoractivityofchimericoncolyticadenovirusfortreatingacutepromyelocyticleukemiacell
AT majiabin interleukin24enhancingantitumoractivityofchimericoncolyticadenovirusfortreatingacutepromyelocyticleukemiacell
AT qinlanyi interleukin24enhancingantitumoractivityofchimericoncolyticadenovirusfortreatingacutepromyelocyticleukemiacell
AT shixiaogang interleukin24enhancingantitumoractivityofchimericoncolyticadenovirusfortreatingacutepromyelocyticleukemiacell
AT sihongqiang interleukin24enhancingantitumoractivityofchimericoncolyticadenovirusfortreatingacutepromyelocyticleukemiacell
AT weiyahui interleukin24enhancingantitumoractivityofchimericoncolyticadenovirusfortreatingacutepromyelocyticleukemiacell